ReviewBioMed research international2019
Exosomes in Cancer: Circulating Immune-Related Biomarkers.
Review in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 50 citations in OpenAlex.
- Exosomes in precision dermatology: From biomarkers to targeted therapeutics in personalized care.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Review
- Oral natural extracellular vesicles for biomedical applications: Advances and clinical perspectives.Journal of advanced research · 2026Review
- Insights into extracellular vesicle-based platforms on the way to cancer treatment.Journal of translational medicine · 2025Review
- Article
- Exosomal miRNAs involvement in pathogenesis, diagnosis, and treatment of rheumatoid arthritis.Heliyon · 2025Review
- A novel tumor-derived exosomal gene signature predicts prognosis in patients with pancreatic cancer.Translational cancer research · 2024Article
- Advancements in Personalized CAR-T Therapy: Comprehensive Overview of Biomarkers and Therapeutic Targets in Hematological Malignancies.International journal of molecular sciences · 2024Review
- Engineered exosomes and composite biomaterials for tissue regeneration.Theranostics · 2024Review
- NKG2A and circulating extracellular vesicles are key regulators of natural killer cell activity in prostate cancer after prostatectomy.Molecular oncology · 2023Article
- Emerging role of exosome-derived non-coding RNAs in tumor-associated angiogenesis of tumor microenvironment.Frontiers in molecular biosciences · 2023Review
- The impacts of exosomes on bone metastatic progression and their potential clinical utility.Bone reports · 2022Article
- MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential.Diagnostics (Basel, Switzerland) · 2022Review
- Serum exosomal proteomics analysis of lung adenocarcinoma to discover new tumor markers.BMC cancer · 2022Article
- Microfluidic Approaches and Methods Enabling Extracellular Vesicle Isolation for Cancer Diagnostics.Micromachines · 2022Review
- The role of Exosomal miRNAs in cancer.Journal of translational medicine · 2022Review
- Plant-derived exosome-like nanoparticles and their therapeutic activities.Asian journal of pharmaceutical sciences · 2022Review
- Alternating exosomes and their mimetics as an emergent strategy for targeted cancer therapy.Frontiers in molecular biosciences · 2022Review
- Small extracellular vesicle-mediated bidirectional crosstalk between neutrophils and tumor cells.Cytokine & growth factor reviews · 2021Review
- The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction.International journal of cancer · 2021Review
- The Role of Tumor-Derived Exosomes in the Abscopal Effect and Immunotherapy.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exosomes, the smallest vesicles (30-100 nm) among multivesicular bodies, are released by all body cells including tumor cells. The cargo they transfer plays an important role in intercellular communication. Tumor-derived exosomes (TEXs) maintain interactions between cancer cells and the microenvironment. Emerging evidence suggests that tumor cells release a large number of exosomes, which may not only influence proximal tumor cells and stromal cells in the local microenvironment but can also exert systemic effects as they are circulating in the blood. TEXs have been shown to boost tumor growth promote progression and metastatic spread via suppression or modification of the immune response towards cancer cells, regulation of tumor neo-angiogenesis, pre-metastatic niche formation, and therapy resistance. In addition, recent studies in patients with cancer suggest that TEXs could serve as tumor biomarker reflecting partially the genetic and molecular content of the parent cancer cell (i.e., as a so-called "liquid biopsy"). Furthermore, recent studies have demonstrated that exosomes may have immunotherapeutic applications, or can act as a drug delivery system for targeted therapies with drugs and biomolecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.